TrialCancer2014

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.